MENTUCCIA, Lucia
 Distribuzione geografica
Continente #
NA - Nord America 350
EU - Europa 91
AS - Asia 9
AF - Africa 4
SA - Sud America 1
Totale 455
Nazione #
US - Stati Uniti d'America 342
IT - Italia 45
FR - Francia 23
DE - Germania 12
CA - Canada 8
CN - Cina 5
SE - Svezia 4
FI - Finlandia 3
ZA - Sudafrica 3
SA - Arabia Saudita 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
CH - Svizzera 1
CL - Cile 1
GH - Ghana 1
ID - Indonesia 1
Totale 455
Città #
Fairfield 44
Santa Cruz 38
Seattle 38
Buffalo 33
Rome 28
Cambridge 21
Houston 19
Woodbridge 19
Ashburn 14
Wilmington 13
Boardman 6
Bremen 5
Chicago 5
Des Moines 5
Los Angeles 5
Ann Arbor 4
Ottawa 4
Phoenix 4
Stockholm 4
Clearwater 3
Helsinki 3
Muizenberg 3
Toronto 3
Büdelsdorf 2
Dallas 2
San Diego 2
San Francisco 2
Scranton 2
Shenyang 2
Atlanta 1
Baotou 1
Beijing 1
Chandler 1
Ciciliano 1
Columbus 1
Falkenstein 1
Frankfurt Am Main 1
Frankfurt am Main 1
Guangzhou 1
Kirkland 1
Kraainem 1
Las Vegas 1
Laurel 1
Levallois-perret 1
Lombard 1
Norma 1
Riva 1
Secaucus 1
Totale 352
Nome #
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study, file e3835321-b842-15e8-e053-a505fe0a3de9 110
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study, file e3835323-6a17-15e8-e053-a505fe0a3de9 101
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab, file e3835323-37d4-15e8-e053-a505fe0a3de9 90
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome, file e3835321-f215-15e8-e053-a505fe0a3de9 74
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e3835322-d440-15e8-e053-a505fe0a3de9 59
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file e383532e-fa2b-15e8-e053-a505fe0a3de9 15
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience, file e3835321-b0d8-15e8-e053-a505fe0a3de9 11
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience, file e3835321-705d-15e8-e053-a505fe0a3de9 8
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e383532a-6618-15e8-e053-a505fe0a3de9 8
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience, file e383531d-6cf8-15e8-e053-a505fe0a3de9 4
Totale 480
Categoria #
all - tutte 920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 920


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201917 0 0 0 0 0 0 0 0 0 0 3 14
2019/2020122 3 2 5 6 21 12 17 14 16 9 10 7
2020/2021107 13 4 4 10 1 14 3 4 17 28 6 3
2021/2022104 5 4 11 3 9 3 6 5 2 5 36 15
2022/202394 8 3 29 23 3 8 6 5 1 0 8 0
2023/202433 1 0 1 2 10 6 5 7 1 0 0 0
Totale 480